170 related articles for article (PubMed ID: 35315197)
1. Developing a translational murine-to-canine pathway for an IL-2/agonist anti-CD40 antibody cancer immunotherapy.
Proksch SF; Matthysen CP; Jardine JE; Wyatt KM; Finlay JR; Nelson DJ
Vet Comp Oncol; 2022 Sep; 20(3):602-612. PubMed ID: 35315197
[TBL] [Abstract][Full Text] [Related]
2. Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy?
Atherton MJ; Lenz JA; Mason NJ
Vet Comp Oncol; 2020 Dec; 18(4):447-470. PubMed ID: 32246517
[TBL] [Abstract][Full Text] [Related]
3. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery.
Baker-Gabb M; Hunt GB; France MP
Aust Vet J; 2003 Dec; 81(12):732-8. PubMed ID: 15080482
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapeutic approaches for canine sarcomas: Pushing the boundaries beyond the conventional.
Borgatti A; Dickerson EB; Lawrence J
Vet Comp Oncol; 2020 Mar; 18(1):9-24. PubMed ID: 31749286
[TBL] [Abstract][Full Text] [Related]
6. Canine transmissible venereal tumour: cytogenetic origin, immunophenotype, and immunobiology. A review.
Mukaratirwa S; Gruys E
Vet Q; 2003 Sep; 25(3):101-11. PubMed ID: 14535580
[TBL] [Abstract][Full Text] [Related]
7. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
[TBL] [Abstract][Full Text] [Related]
8. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase.
Jackaman C; Lansley S; Allan JE; Robinson BW; Nelson DJ
Int Immunol; 2012 Jun; 24(6):357-68. PubMed ID: 22354912
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations.
Bubeník J; Indrová M; Toulcová A
Folia Biol (Praha); 1986; 32(6):384-91. PubMed ID: 3492396
[TBL] [Abstract][Full Text] [Related]
10. The potential of the combined use of targeted type I interferon pathway inhibitors and oncolytic viruses to treat sarcomas.
MacNeill AL
Vet Comp Oncol; 2020 Mar; 18(1):36-42. PubMed ID: 31618515
[TBL] [Abstract][Full Text] [Related]
11. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2306782120. PubMed ID: 37607227
[TBL] [Abstract][Full Text] [Related]
12. Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer.
Cicchelero L; Denies S; Haers H; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
Vet Comp Oncol; 2017 Dec; 15(4):1187-1205. PubMed ID: 27506827
[TBL] [Abstract][Full Text] [Related]
13. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
[TBL] [Abstract][Full Text] [Related]
14. Soft tissue sarcoma in the dog - part 1: a current review.
Bray JP
J Small Anim Pract; 2016 Oct; 57(10):510-519. PubMed ID: 27624929
[TBL] [Abstract][Full Text] [Related]
15. Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma.
Guth AM; Hafeman SD; Elmslie RE; Dow SW
Vet Comp Oncol; 2013 Dec; 11(4):296-305. PubMed ID: 22540967
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2.
Schultze JL; Anderson KC; Gilleece MH; Gribben JG; Nadler LM
Br J Haematol; 2001 May; 113(2):455-60. PubMed ID: 11380416
[TBL] [Abstract][Full Text] [Related]
17. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.
Weiss JM; Back TC; Scarzello AJ; Subleski JJ; Hall VL; Stauffer JK; Chen X; Micic D; Alderson K; Murphy WJ; Wiltrout RH
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19455-60. PubMed ID: 19892741
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.
Cardoso JMO; Brito RCF; Mathias FAS; Reis LES; Vieira JFP; Ostolin TLVDP; Andrade HM; Ramos GS; Frézard F; Aguiar-Soares RDO; Roatt BM; Reis AB
Mol Immunol; 2022 Jan; 141():70-78. PubMed ID: 34814056
[TBL] [Abstract][Full Text] [Related]
19. Intra-operative cisplatin for the treatment of canine extremity soft tissue sarcomas.
Havlicek M; Straw RS; Langova V; Dernell WS
Vet Comp Oncol; 2009 Jun; 7(2):122-9. PubMed ID: 19453366
[TBL] [Abstract][Full Text] [Related]
20. Comparative pathology of canine soft tissue sarcomas: possible models of human non-rhabdomyosarcoma soft tissue sarcomas.
Milovancev M; Hauck M; Keller C; Stranahan LW; Mansoor A; Malarkey DE
J Comp Pathol; 2015 Jan; 152(1):22-7. PubMed ID: 25435513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
